<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00576693</url>
  </required_header>
  <id_info>
    <org_study_id>R01NS058728-01A1</org_study_id>
    <secondary_id>NINDS</secondary_id>
    <secondary_id>CRC</secondary_id>
    <secondary_id>1U01NS058728-01A1</secondary_id>
    <nct_id>NCT00576693</nct_id>
  </id_info>
  <brief_title>Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis</brief_title>
  <acronym>SAMMPRIS</acronym>
  <official_title>Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marc Chimowitz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PRIMARY HYPOTHESIS:

      Compared with intensive medical therapy alone, intracranial angioplasty and stenting combined
      with intensive medical therapy will decrease the risk of the primary endpoint by 35% over a
      mean follow-up of two years in high-risk patients patients with 70% - 99% intracranial
      stenosis who had a transient ischemic attack (TIA) or stroke within 30 days prior to
      enrollment) with symptomatic stenosis of a major intracranial artery.

      SUMMARY:

      The best treatment for prevention of another stroke or TIA in patients with narrowing of one
      of the arteries in the brain is uncertain. A common treatment is the use of anti-clotting
      medications to prevent blood clots from forming in the narrowed vessel. There are a variety
      of medicines used for this purpose. These medications are usually taken for the rest of a
      patient's life.

      However, a treatment that has been used successfully together with anti-clotting medications
      in patients with narrowing of the blood vessels of the heart is now being studied in the
      blood vessels of the brain. This treatment is called stenting.

      Recent research has also indicated a benefit in prevention of recurring stroke by Intensive
      Medical Therapy, which is defined as treating risk factors for stroke like high blood
      pressure, elevated LDL (low density lipids - the &quot;bad&quot; form of cholesterol) and diabetes. The
      purpose of this study is to compare the safety and effectiveness of either Intensive Medical
      Therapy PLUS Stenting or Intensive Medical Therapy ONLY in preventing stroke, heart attacks
      or death.

      The study will enroll patients over a 5 year period. Each participant will be involved in the
      study for a minimum of 1 year and a maximum of 3 years.

      Fifty different medical centers in the United States are part of this study. Both the
      Clinical Coordinating Center and the Statistical Coordinating Center for the entire study
      will be located at Emory University.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be an investigator initiated and designed Phase III multicenter trial in which
      patients with TIA or non-disabling stroke within 30 days prior to enrollment that is caused
      by 70% - 99% stenosis of a major intracranial artery (MCA, carotid, vertebral, or basilar)
      will be randomized (1:1) at approximately 50 sites to:

      intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg
      per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel
      beyond 90 days for a cardiac indication, and aggressive risk factor management primarily
      targeting blood pressure &lt; 140 / 90 mm Hg (&lt; 130 / 80 if diabetic) and LDL &lt; 70 mg / dl)

      OR

      intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding
      nitinol stent (or any future FDA approved iterations of the balloon, stent, or the delivery
      systems) plus intensive medical therapy (aspirin 325 mg / day for entire follow-up,
      clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends
      continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor
      management primarily targeting blood pressure &lt; 140 / 90 mm Hg (&lt; 130 / 80 if diabetic) and
      LDL &lt; 70 mg / dl).

      Risk factor management will be performed by the study neurologist at each site who will be
      assisted by an innovative, evidence-based, educational, lifestyle modification program
      (INTERxVENT) that will be administered at regularly scheduled times to all patients
      throughout the study.

      All patients enrolled in the trial will be followed until the first of the following: 90 days
      after a primary endpoint, death, or the close-out visit in the trial, which will occur within
      a window from 60 days before March 31, 2012 to 30 days after March 31, 2013. Patients who do
      not die or have a primary endpoint during follow-up will be followed for 2-4.5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Any Stroke or Death Within 30 Days of Enrollment or Any Revascularization Procedure OR an Ischemic Stroke in the Territory of the Symptomatic Intracranial Artery Beyond 30 Days After Enrollment.</measure>
    <time_frame>Mean length of follow-up was 2.4 years</time_frame>
    <description>Any stroke (ischemic, parenchymal brain hemorrhage, subarachnoid or intraventricular hemorrhage) or death within 30 days after enrollment OR any stroke (ischemic, parenchymal brain hemorrhage, subarachnoid or intraventricular hemorrhage) or death within 30 days of any revascularization procedure of the qualifying symptomatic intracranial artery done during follow-up, OR an ischemic stroke in the territory of the symptomatic intracranial artery from day 31 after study entry to completion of follow-up.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">451</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>intensive medical management plus stenting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent (or any future FDA approved iterations of the balloon, stent, or the delivery systems) plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure &lt; 140 / 90 mm Hg (&lt; 130 / 80 if diabetic) and LDL &lt; 70 mg / dl).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intensive medical management alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure &lt; 140 / 90 mm Hg (&lt; 130 / 80 if diabetic) and LDL &lt; 70 mg / dl)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>intracranial angioplasty and stenting</intervention_name>
    <description>intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent (or any future FDA approved iterations of the balloon, stent, or the delivery systems) plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure &lt; 140 / 90 mm Hg (&lt; 130 / 80 if diabetic) and LDL &lt; 70 mg / dl).</description>
    <arm_group_label>intensive medical management plus stenting</arm_group_label>
    <other_name>Wingspan stent</other_name>
    <other_name>Gateway balloon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>intensive medical management</intervention_name>
    <description>intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure &lt; 140 / 90 mm Hg (&lt; 130 / 80 if diabetic) and LDL &lt; 70 mg / dl)</description>
    <arm_group_label>intensive medical management alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          1. Transient ischemic attack (TIA) or non-severe stroke within 30 days of enrollment
             attributed to 70-99% stenosis of a major intracranial artery (carotid artery, MCA stem
             (M1), vertebral artery, or basilar artery)

             • may be diagnosed byTranscranial Doppler (TCD), Magnetic Resonance Angiogram (MRA),
             or computed tomography angiography (CTA) to qualify for angiogram performed as part of
             the study protocol but must be confirmed by catheter angiography for enrollment in the
             trial

          2. Modified Rankin score of ≤ 3

          3. Target area of stenosis in an intracranial artery that has a normal diameter of 2.00
             mm to 4.50 mm

          4. Target area of stenosis is less than or equal to 14 mm in length

          5. Age ≥ 30 years and ≤ 80 years.

             • Patients 30-49 years are required to meet at least one additional criteria (i-vi)
             provided in the table below to qualify for the study. This additional requirement is
             to increase the likelihood that the symptomatic intracranial stenosis in patients
             30-49 years is atherosclerotic.

             i. insulin dependent diabetes for at least 15 years ii. at least 2 of the following
             atherosclerotic risk factors: hypertension (BP &gt; 140/90 or on antihypertensive
             therapy); dyslipidemia (LDL &gt; 130 mg /dl or HDL &lt; 40 mg/dl or fasting triglycerides &gt;
             150 mg/dl or on lipid lowering therapy); smoking; non-insulin dependent diabetes or
             insulin dependent diabetes of less than 15 years duration; family history of any of
             the following: myocardial infarction, coronary artery bypass, coronary angioplasty or
             stenting, stroke, carotid endarterectomy or stenting, peripheral vascular surgery in
             parent or sibling who was &lt; 55 years of age for men or &lt; 65 for women at the time of
             the event ii. history of any of the following: myocardial infarction, coronary artery
             bypass, coronary angioplasty or stenting, carotid endarterectomy or stenting, or
             peripheral vascular surgery for atherosclerotic disease iv. any stenosis of an
             extracranial carotid or vertebral artery, another intracranial artery, subclavian
             artery, coronary artery, iliac or femoral artery, other lower or upper extremity
             artery, mesenteric artery, or renal artery that was documented by non-invasive
             vascular imaging or catheter angiography and is considered atherosclerotic v. aortic
             arch atheroma documented by non-invasive vascular imaging or catheter angiography vi.
             any aortic aneurysm documented by non-invasive vascular imaging or catheter
             angiography that is considered atherosclerotic

          6. Negative pregnancy test in a female who has had any menses in the last 18 months

          7. Patient is willing and able to return for all follow-up visits required by the
             protocol

          8. Patient is available by phone

          9. Patient understands the purpose and requirements of the study, can make him/herself
             understood, and has provided informed consent

        EXCLUSION CRITERIA

          1. Tandem extracranial or intracranial stenosis (70%-99%) or occlusion that is proximal
             or distal to the target intracranial lesion (NOTE: an exception is allowed if the
             occlusion involves a single vertebral artery proximal to a symptomatic basilar artery
             stenosis and the contralateral vertebral artery is supplying the basilar artery)

          2. Bilateral intracranial vertebral artery stenosis of 70%-99% and uncertainty about
             which artery is symptomatic (e.g. if patient has pontine, midbrain, or temporal -
             occipital symptoms)

          3. Stenting, angioplasty, or endarterectomy of an extracranial (carotid or vertebral
             artery) or intracranial artery within 30 days prior to expected enrollment date

          4. Previous treatment of target lesion with a stent, angioplasty, or other mechanical
             device, or plan to perform staged angioplasty followed by stenting of target lesion

          5. Plan to perform concomitant angioplasty or stenting of an extracranial vessel tandem
             to an intracranial stenosis

          6. Presence of intraluminal thrombus proximal to or at the target lesion

          7. Any aneurysm proximal to or distal to stenotic intracranial artery

          8. Intracranial tumor (except meningioma) or any intracranial vascular malformation

          9. CT or angiographic evidence of severe calcification at target lesion

         10. Thrombolytic therapy within 24 hours prior to enrollment

         11. Progressive neurological signs within 24 hours prior to enrollment

         12. Brain infarct within previous 30 days of enrollment that is of sufficient size (&gt; 5
             cms) to be at risk of hemorrhagic conversion during or after stenting

         13. Any hemorrhagic infarct within 14 days prior to enrollment

         14. Any hemorrhagic infarct within 15 - 30 days that is associated with mass effect

         15. Any history of a primary intracerebral (parenchymal) hemorrhage (ICH)

         16. Any other intracranial hemorrhage (subarachnoid, subdural, epidural) within 30 days

         17. Any untreated chronic subdural hematoma of greater than 5 mm in thickness

         18. Intracranial arterial stenosis due to arterial dissection, Moya Moya disease; any
             known vasculitic disease; herpes zoster, varicella zoster or other viral vasculopathy;
             neurosyphilis; any other intracranial infection; any intracranial stenosis associated
             with Cerebrospinal fluid (CSF) pleocytosis; radiation induced vasculopathy;
             fibromuscular dysplasia; sickle cell disease; neurofibromatosis; benign angiopathy of
             central nervous system; post-partum angiopathy; suspected vasospastic process,
             suspected recanalized embolus

         19. Presence of any of the following unequivocal cardiac sources of embolism: chronic or
             paroxysmal atrial fibrillation, mitral stenosis, mechanical valve, endocarditis,
             intracardiac clot or vegetation, myocardial infarction within three months, dilated
             cardiomyopathy, left atrial spontaneous echo contrast, ejection fraction less than 30%

         20. Known allergy or contraindication to aspirin, clopidogrel, heparin, nitinol, local or
             general anesthesia

         21. History of life-threatening allergy to contrast dye. If not life threatening and can
             be effectively pretreated, patient can be enrolled at physician's discretion

         22. Active peptic ulcer disease, major systemic hemorrhage within 30 days, active bleeding
             diathesis, platelets &lt; 100,000, hematocrit &lt; 30, International normalized ratio (INR)
             &gt; 1.5, clotting factor abnormality that increases the risk of bleeding, current
             alcohol or substance abuse, uncontrolled severe hypertension (systolic pressure &gt; 180
             mm Hg or diastolic pressure &gt; 115 mm Hg), severe liver impairment Aspartate
             Transaminase (AST) or Alanine transaminase (ALT) &gt; 3 x normal, cirrhosis, creatinine &gt;
             3.0 (unless on dialysis)

         23. Major surgery (including open femoral, aortic, or carotid surgery) within previous 30
             days or planned in the next 90 days after enrollment

         24. Indication for warfarin or heparin beyond enrollment (NOTE: exceptions allowed for use
             of systemic heparin during stenting procedure or subcutaneous heparin for deep vein
             thrombosis (DVT) prophylaxis while hospitalized)

         25. Severe neurological deficit that renders the patient incapable of living independently

         26. Dementia or psychiatric problem that prevents the patient from following an outpatient
             program reliably

         27. Co-morbid conditions that may limit survival to less than 3 years

         28. Pregnancy or of childbearing potential and unwilling to use contraception for the
             duration of this study

         29. Enrollment in another study that would conflict with the current study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc I Chimowitz, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barrow Neurological Institute - St. Joseph's Hospital and Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glendale Adventist</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida - Shands</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30388</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central DuPage Hospital</name>
      <address>
        <city>Winfield</city>
        <state>Illinois</state>
        <zip>60190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence St. John</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moses Cone Medical Center</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forsyth Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19170</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburg</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erlanger Medical Center</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor St. Luke's</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White - Texas A&amp;M</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentera</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacred Heart Medical Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MultiCare</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nlm.nih.gov/databases/alerts/intracranial_arterial_stenosis.html</url>
    <description>Clinical Alert</description>
  </link>
  <results_reference>
    <citation>Derdeyn CP, Fiorella D, Lynn MJ, Barnwell SL, Zaidat OO, Meyers PM, Gobin YP, Dion J, Lane BF, Turan TN, Janis LS, Chimowitz MI; SAMMPRIS Trial Investigators. Impact of operator and site experience on outcomes after angioplasty and stenting in the SAMMPRIS trial. J Neurointerv Surg. 2013 Nov;5(6):528-33. doi: 10.1136/neurintsurg-2012-010504. Epub 2012 Sep 12.</citation>
    <PMID>22977278</PMID>
  </results_reference>
  <results_reference>
    <citation>Turan TN, Lynn MJ, Nizam A, Lane B, Egan BM, Le NA, Lopes-Virella MF, Hermayer KL, Benavente O, White CL, Brown WV, Caskey MF, Steiner MR, Vilardo N, Stufflebean A, Derdeyn CP, Fiorella D, Janis S, Chimowitz MI; SAMMPRIS Investigators. Rationale, design, and implementation of aggressive risk factor management in the Stenting and Aggressive Medical Management for Prevention of Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) trial. Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):e51-60.</citation>
    <PMID>22991350</PMID>
  </results_reference>
  <results_reference>
    <citation>Fiorella D, Derdeyn CP, Lynn MJ, Barnwell SL, Hoh BL, Levy EI, Harrigan MR, Klucznik RP, McDougall CG, Pride GL Jr, Zaidat OO, Lutsep HL, Waters MF, Hourihane JM, Alexandrov AV, Chiu D, Clark JM, Johnson MD, Torbey MT, Rumboldt Z, Cloft HJ, Turan TN, Lane BF, Janis LS, Chimowitz MI; SAMMPRIS Trial Investigators. Detailed analysis of periprocedural strokes in patients undergoing intracranial stenting in Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS). Stroke. 2012 Oct;43(10):2682-8. Epub 2012 Sep 13.</citation>
    <PMID>22984008</PMID>
  </results_reference>
  <results_reference>
    <citation>Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, Janis LS, Lutsep HL, Barnwell SL, Waters MF, Hoh BL, Hourihane JM, Levy EI, Alexandrov AV, Harrigan MR, Chiu D, Klucznik RP, Clark JM, McDougall CG, Johnson MD, Pride GL Jr, Torbey MT, Zaidat OO, Rumboldt Z, Cloft HJ; SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011 Sep 15;365(11):993-1003. doi: 10.1056/NEJMoa1105335. Epub 2011 Sep 7. Erratum in: N Engl J Med. 2012 Jul 5;367(1):93.</citation>
    <PMID>21899409</PMID>
  </results_reference>
  <results_reference>
    <citation>Derdeyn CP, Chimowitz MI, Lynn MJ, Fiorella D, Turan TN, Janis LS, Montgomery J, Nizam A, Lane BF, Lutsep HL, Barnwell SL, Waters MF, Hoh BL, Hourihane JM, Levy EI, Alexandrov AV, Harrigan MR, Chiu D, Klucznik RP, Clark JM, McDougall CG, Johnson MD, Pride GL Jr, Lynch JR, Zaidat OO, Rumboldt Z, Cloft HJ; Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial Investigators. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet. 2014 Jan 25;383(9914):333-41. doi: 10.1016/S0140-6736(13)62038-3. Epub 2013 Oct 26.</citation>
    <PMID>24168957</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2007</study_first_submitted>
  <study_first_submitted_qc>December 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2007</study_first_posted>
  <results_first_submitted>May 6, 2014</results_first_submitted>
  <results_first_submitted_qc>June 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 11, 2014</results_first_posted>
  <last_update_submitted>June 10, 2014</last_update_submitted>
  <last_update_submitted_qc>June 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Marc Chimowitz</investigator_full_name>
    <investigator_title>Full Professor</investigator_title>
  </responsible_party>
  <keyword>ischemic stroke</keyword>
  <keyword>intracranial stenting</keyword>
  <keyword>vascular risk factor management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intensive Medical Management Plus Stenting</title>
          <description>intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure &lt; 140 / 90 mm Hg (&lt; 130 / 80 if diabetic) and LDL &lt; 70 mg / dl).
intracranial angioplasty and stenting: intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent (or any future FDA approved iterations of the balloon, stent, or the delivery systems) plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardia</description>
        </group>
        <group group_id="P2">
          <title>Intensive Medical Management Alone</title>
          <description>Intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure &lt; 140 / 90 mm Hg (&lt; 130 / 80 if diabetic) and LDL &lt; 70 mg / dl)
intensive medical management: intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure &lt; 140 / 90 mm Hg (&lt; 130 / 80 if diabetic) and LDL &lt; 70 mg / dl)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="224"/>
                <participants group_id="P2" count="227"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="214"/>
                <participants group_id="P2" count="203"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intensive Medical Management Plus Stenting</title>
          <description>intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure &lt; 140 / 90 mm Hg (&lt; 130 / 80 if diabetic) and LDL &lt; 70 mg / dl).
intracranial angioplasty and stenting: intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent (or any future FDA approved iterations of the balloon, stent, or the delivery systems) plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardia</description>
        </group>
        <group group_id="B2">
          <title>Intensive Medical Management Alone</title>
          <description>Intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure &lt; 140 / 90 mm Hg (&lt; 130 / 80 if diabetic) and LDL &lt; 70 mg / dl)
intensive medical management: intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure &lt; 140 / 90 mm Hg (&lt; 130 / 80 if diabetic) and LDL &lt; 70 mg / dl)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="224"/>
            <count group_id="B2" value="227"/>
            <count group_id="B3" value="451"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.0" spread="10.7"/>
                    <measurement group_id="B2" value="59.5" spread="11.8"/>
                    <measurement group_id="B3" value="60.2" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="162"/>
                    <measurement group_id="B3" value="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Hypertension</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                    <measurement group_id="B2" value="203"/>
                    <measurement group_id="B3" value="403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Lipid Disorder</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking</title>
          <description>Based on the Physician-based Assessment and Counseling for Exercise (PACE) Smoking Score.
The data value for smoking status was missing for 1 patient in the intensive medical management plus stenting group.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Previously</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <description>A patient is considered diabetic at baseline if there is a history of diabetes or if the baseline hemoglobin A1c &gt; 6.5%.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143.9" spread="20.6"/>
                    <measurement group_id="B2" value="146.8" spread="21.8"/>
                    <measurement group_id="B3" value="145.4" spread="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low Density Lipoprotein Cholesterol</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96.2" spread="38.4"/>
                    <measurement group_id="B2" value="97.7" spread="36.6"/>
                    <measurement group_id="B3" value="97.0" spread="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.3" spread="6.2"/>
                    <measurement group_id="B2" value="30.7" spread="6.3"/>
                    <measurement group_id="B3" value="30.5" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Coronary Artery Disease</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Stroke (Not Qualifying Event)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Qualifying Event</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>On Antithrombotic Therapy at Qualifying Event</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from Qualifying Event to Randomization</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" lower_limit="4" upper_limit="16"/>
                    <measurement group_id="B2" value="7" lower_limit="4" upper_limit="19"/>
                    <measurement group_id="B3" value="7" lower_limit="4" upper_limit="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Symptomatic Qualifying Artery</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Internal Carotid Artery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Middle Cerebral Artery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vertebral Artery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basilar Artery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percent Stenosis of Symptomatic Qualifying Artery</title>
          <description>According to a reading of the cerebral angiogram by the site interventionist.</description>
          <units>% of the diameter the artery</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80" spread="7"/>
                    <measurement group_id="B2" value="81" spread="7"/>
                    <measurement group_id="B3" value="81" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Any Stroke or Death Within 30 Days of Enrollment or Any Revascularization Procedure OR an Ischemic Stroke in the Territory of the Symptomatic Intracranial Artery Beyond 30 Days After Enrollment.</title>
        <description>Any stroke (ischemic, parenchymal brain hemorrhage, subarachnoid or intraventricular hemorrhage) or death within 30 days after enrollment OR any stroke (ischemic, parenchymal brain hemorrhage, subarachnoid or intraventricular hemorrhage) or death within 30 days of any revascularization procedure of the qualifying symptomatic intracranial artery done during follow-up, OR an ischemic stroke in the territory of the symptomatic intracranial artery from day 31 after study entry to completion of follow-up.</description>
        <time_frame>Mean length of follow-up was 2.4 years</time_frame>
        <population>All patients enrolled in the study were included in the primary outcome analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Intensive Medical Management Plus Stenting</title>
            <description>intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure &lt; 140 / 90 mm Hg (&lt; 130 / 80 if diabetic) and LDL &lt; 70 mg / dl).
intracranial angioplasty and stenting: intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent (or any future FDA approved iterations of the balloon, stent, or the delivery systems) plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardia</description>
          </group>
          <group group_id="O2">
            <title>Intensive Medical Management Alone</title>
            <description>Intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure &lt; 140 / 90 mm Hg (&lt; 130 / 80 if diabetic) and LDL &lt; 70 mg / dl)
intensive medical management: intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure &lt; 140 / 90 mm Hg (&lt; 130 / 80 if diabetic) and LDL &lt; 70 mg / dl)</description>
          </group>
        </group_list>
        <measure>
          <title>Any Stroke or Death Within 30 Days of Enrollment or Any Revascularization Procedure OR an Ischemic Stroke in the Territory of the Symptomatic Intracranial Artery Beyond 30 Days After Enrollment.</title>
          <description>Any stroke (ischemic, parenchymal brain hemorrhage, subarachnoid or intraventricular hemorrhage) or death within 30 days after enrollment OR any stroke (ischemic, parenchymal brain hemorrhage, subarachnoid or intraventricular hemorrhage) or death within 30 days of any revascularization procedure of the qualifying symptomatic intracranial artery done during follow-up, OR an ischemic stroke in the territory of the symptomatic intracranial artery from day 31 after study entry to completion of follow-up.</description>
          <population>All patients enrolled in the study were included in the primary outcome analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical analysis was based on a comparison of the of the two treatment groups with respect to the time to a primary outcome using the logrank test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0252</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Mean length of follow-up was 2.4 years</time_frame>
      <desc>The prespecified study outcomes were explicitly requested on the adverse event form. Any other adverse event was to be reported if it was either serious or related to a study intervention according to prespecified criteria and classified on the adverse event form using the Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.</desc>
      <group_list>
        <group group_id="E1">
          <title>Intensive Medical Management Plus Stenting</title>
          <description>intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure &lt; 140 / 90 mm Hg (&lt; 130 / 80 if diabetic) and LDL &lt; 70 mg / dl).
intracranial angioplasty and stenting: intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent (or any future FDA approved iterations of the balloon, stent, or the delivery systems) plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardia</description>
        </group>
        <group group_id="E2">
          <title>Intensive Medical Management Alone</title>
          <description>Intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure &lt; 140 / 90 mm Hg (&lt; 130 / 80 if diabetic) and LDL &lt; 70 mg / dl)
intensive medical management: intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure &lt; 140 / 90 mm Hg (&lt; 130 / 80 if diabetic) and LDL &lt; 70 mg / dl)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="146" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood / Bone Marrow</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Coagulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Lymphatics</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Hemorrhage / Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Study Protocol">Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Cardiac Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Cardiac General</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Auditory / Ear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular / Visual</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Study Protocol">Systemic Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Constitutional Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title vocab="Study Protocol">Death</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary / Pancreas</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy / Immunology</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic / Laaboratory</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal / Soft Tissue</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Study Protocol">Ischemic Stroke in the Territory of Qualifying Symptomatic Artery</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title vocab="Study Protocol">Ischemic Stroke Not in the Territory of the Qualifying Symptomatic Artery</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title vocab="Study Protocol">Symptomatic Intracranial Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title vocab="Study Protocol">Intracranial Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title vocab="Study Protocol">Transient Ischemic Attack / Cerebral Infarct with Temporary Signs</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Neurology</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title vocab="Study Protocol">Asymptomatic Intracranial Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal / Genitourinary</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Sexual / Reproductive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary / Upper Respiratory</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology / Skin</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgery / Intraoperative Injury</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title vocab="Study Protocol">Pulmonary Embolus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title vocab="Study Protocol">Cerebral Venous Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title vocab="Study Protocol">Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title vocab="Study Protocol">Complications of Acute Ischemia of a Limb or Internal Organ</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac General</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Study Protocol">Systemic Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic / Laboratory</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal / Soft Tissue</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Study Protocol">Transient Ischemic Attack / Cerebral Infarct with Temporary Signs</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>Neurology</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary / Upper Respiratory</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marc I. Chimowitz, MBChB</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-3020</phone>
      <email>mchimow@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

